Phase II clinical study of neoadjuvant chemotherapy with CDDP-CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky massReportar como inadecuado




Phase II clinical study of neoadjuvant chemotherapy with CDDP-CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

International Journal of Clinical Oncology

, Volume 21, Issue 6, pp 1120–1127

First Online: 24 June 2016Received: 02 March 2016Accepted: 14 June 2016DOI: 10.1007-s10147-016-1008-7

Cite this article as: Shoji, T., Takatori, E., Furutake, Y. et al. Int J Clin Oncol 2016 21: 1120. doi:10.1007-s10147-016-1008-7

Abstract

BackgroundWe examined the efficacy and safety of neoadjuvant chemotherapy NAC with the CPT-11 + CDDP regimen in combination with radical hysterectomy.

Subjects and methodsThe subjects were 42 patients with stages IB2 to IIIB squamous cell carcinoma of the uterine cervix with a bulky mass. CDDP at 70 mg-m was intravenously administered on day 1 and CPT-11 at 70 mg-m was intravenously administered on days 1 and 8 of a 21-day cycle. In principle, two cycles were administered followed by radical hysterectomy. We examined antitumor efficacy, adverse events, completion rate of radical hysterectomy, operative time, surgical blood loss, progression-free survival PFS, and overall survival OS.

ResultsThe antitumor effect was complete response in 7 patients, partial response in 28, stable disease in 6, and progressive disease in 1; the response rate was 83.3 % 95 % confidence interval, 68.6–93.0. Grade 3 or more severe neutropenia, anemia, and platelet count decreases were noted in 23 54.8 %, 4 9.5 %, and 1 2.4 % patient, respectively. Grade 3 nausea occurred in 3 patients 7.1 %, vomiting in 1 2.4 %, and grade 3 febrile neutropenia in 2 7.1 %. The completion rate of radical hysterectomy was 88.1 %. The median operative time and surgical blood loss were 260 min range, 210–334 and 500 ml range, 393–898, respectively. The 5-year PFS rate was 67.2 %, and the 5-year OS rate was 68.0 %. In multivariate analysis, lymph node metastasis before NAC hazard ratio HR, 34.88 and non-response to NAC HR 30.58 were significant prognostic factors.

ConclusionNAC with the CDDP-CPT-11 regimen achieves a high antitumor efficacy with moderate adverse reactions, allowing safe radical hysterectomy, and is thus considered to be a useful therapeutic method that can improve prognosis.

KeywordsCervical cancer Bulky mass NAC CDDP CPT-11  Download fulltext PDF



Autor: Tadahiro Shoji - Eriko Takatori - Yoko Furutake - Anna Takada - Takayuki Nagasawa - Hideo Omi - Masahiro Kagabu - Tatsuya 

Fuente: https://link.springer.com/







Documentos relacionados